Diagnosis and management of primary biliary cirrhosis

References

• Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis 1999;3:529-70
   PubMedGoogle Scholar
• Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis. chronic non-suppurative destructive cholangitis. Am J Pathol 1965;46:387-407
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Mackay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525-31
   PubMed Web of Science ®Google Scholar
• Cha S, Leung PS, Gershwin ME, et al. Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proc Natl Acad Sci USA 1993;90:2527-31
   PubMed Web of Science ®Google Scholar
• Mutimer DJ, Fussey SP, Yeaman SJ, et al. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989;10:403-7
   PubMed Web of Science ®Google Scholar
• Ahrens EH Jr, Payne MA, Kunkel HG, et al. Primary biliary cirrhosis. Medicine (Baltimore) 1950;29:299-364
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003;362:53-61
   PubMed Web of Science ®Google Scholar
• Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003;125:1476-9
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-202
   PubMed Web of Science ®Google Scholar
• Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010;59:508-12
   PubMed Web of Science ®Google Scholar
• Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 2014;34:e31-8
   PubMed Web of Science ®Google Scholar
• Kim WR, Lindor KD, Locke GR III, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631-6
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Salomaa V, Niemela S, et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007;42:1347-53
   PubMed Web of Science ®Google Scholar
• Danielsson A, Boqvist L, Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 1990;11:458-64
   PubMed Web of Science ®Google Scholar
• Eriksson S, Lindgren S. The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. Scand J Gastroenterol 1984;19:971-6
   PubMed Web of Science ®Google Scholar
• Hamlyn AN, Macklon AF, James O. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. Gut 1983;24:940-5
   PubMed Web of Science ®Google Scholar
• James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999;30:390-4
   PubMed Web of Science ®Google Scholar
• Lofgren J, Jarnerot G, Danielsson D, et al. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol 1985;20:647-50
   PubMed Web of Science ®Google Scholar
• Myszor M, James OF. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med 1990;75:377-85
   PubMedGoogle Scholar
• Remmel T, Remmel H, Uibo R, et al. Primary biliary cirrhosis in Estonia. With special reference to incidence, prevalence, clinical features, and outcome. Scand J Gastroenterol 1995;30:367-71
   PubMed Web of Science ®Google Scholar
• Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990;12:98-105
   PubMed Web of Science ®Google Scholar
• Ray-Chadhuri D, Rigney E, MacComack K. Epidemiology of PBC in Sheffield updated: demographics and relation to water supply. British Association for the Study of the Liver; London: 2001. p. 42
   Google Scholar
• Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J 1980;281:772-5
   PubMed Web of Science ®Google Scholar
• Liang Y, Yang Z, Zhong R. Smoking, family history and urinary tract infection are associated with primary biliary cirrhosis: a meta-analysis. Hepatol Res 2011;41:572-8
   PubMed Web of Science ®Google Scholar
• Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006;43:525-31
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011;31:147-56
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013;8:303-30
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007;46:785-92
   PubMed Web of Science ®Google Scholar
• Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127:485-92
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Baragiotta A, Heneghan MA, et al. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 2006;44:667-74
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010;42:655-7
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544-55
   PubMed Web of Science ®Google Scholar
• Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010;42:658-60
   PubMed Web of Science ®Google Scholar
• Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011;43:329-32
   PubMed Web of Science ®Google Scholar
• Zinn AR. The X chromosome and the ovary. J Soc Gynecol Investig 2001;8:S34-6
   PubMedGoogle Scholar
• Ranke MB, Saenger P. Turner’s syndrome. Lancet 2001;358:309-14
   PubMed Web of Science ®Google Scholar
• Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001;2:777-80
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004;363:533-5
   PubMed Web of Science ®Google Scholar
• Miozzo M, Selmi C, Gentilin B, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007;46:456-62
   PubMed Web of Science ®Google Scholar
• MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003;7:941-56, ix
   PubMedGoogle Scholar
• Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol 2003;39:142-8
   PubMed Web of Science ®Google Scholar
• Neuberger J. Liver transplantation for primary biliary cirrhosis. Autoimmun Rev 2003;2:1-7
   PubMed Web of Science ®Google Scholar
• Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399-402
   PubMed Web of Science ®Google Scholar
• Locke GR III, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996;23:52-6
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50:291-308
   PubMed Web of Science ®Google Scholar
• Imam MH, Lindor KD. The natural history of primary biliary cirrhosis. Semin Liver Dis 2014;34:329-33
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-73
   PubMed Web of Science ®Google Scholar
• Newton JL, Bhala N, Burt J, et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol 2006;44:776-83
   PubMed Web of Science ®Google Scholar
• Jones DE, Bhala N, Burt J, et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006;55:536-41
   PubMed Web of Science ®Google Scholar
• Jones DE, Bhala N, Newton JL. Reflections on therapeutic trials in primary biliary cirrhosis: a quality of life oriented counter-view. Hepatology 2006;43:633; author reply 4
   PubMed Web of Science ®Google Scholar
• Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006;44:91-8
   PubMed Web of Science ®Google Scholar
• Stanca CM, Bach N, Krause C, et al. Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 2005;100:1104-9
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Kalaitzakis E, Neuhauser M, et al. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int 2010;30:251-8
   PubMed Web of Science ®Google Scholar
• Jones DE, Al-Rifai A, Frith J, et al. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol 2010;53:911-17
   PubMed Web of Science ®Google Scholar
• Zein CO, McCullough AJ. Association between fatigue and decreased survival in primary biliary cirrhosis. Gut 2007;56:1165-6; author reply 6
   PubMed Web of Science ®Google Scholar
• Newton JL. Fatigue in primary biliary cirrhosis. Clin Liver Dis 2008;12:367-83; ix
   PubMed Web of Science ®Google Scholar
• Hollingsworth KG, Newton JL, Taylor R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol2008;6:1041-8
   PubMed Web of Science ®Google Scholar
• Newton JL, Hollingsworth KG, Taylor R, et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 2008;48:541-9
   PubMed Web of Science ®Google Scholar
• Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013;58:273-83
   PubMed Web of Science ®Google Scholar
• Pells G, Mells GF, Carbone M, et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol 2013;59:67-73
   PubMed Web of Science ®Google Scholar
• Carbone M, Bufton S, Monaco A, et al. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 2013;59:490-4
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003;1:297-302
   PubMed Web of Science ®Google Scholar
• Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999;29:1003-6
   PubMed Web of Science ®Google Scholar
• Crowe J, Christensen E, Doniach D, et al. Early features of primary biliary cirrhosis: an analysis of 85 patients. Am J Gastroenterol 1985;80:466-8
   PubMed Web of Science ®Google Scholar
• Ng VL, Ryckman FC, Porta G, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000;30:152-6
   PubMed Web of Science ®Google Scholar
• Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139:1008-18; 18.e1
   PubMed Web of Science ®Google Scholar
• Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014;60:399-407
   PubMed Web of Science ®Google Scholar
• Carey EJ. Cholestatic liver disease. Springer; New York: 2014
   Google Scholar
• Koh WH, Dunphy J, Whyte J, et al. Characterisation of anticytoplasmic antibodies and their clinical associations. Ann Rheum Dis 1995;54:269-73
   PubMed Web of Science ®Google Scholar
• Walker JG, Doniach D, Roitt IM, et al. Serological Tests in Diagnosis of Primary Biliary Cirrhosis. Lancet 1965;1:827-31
   PubMed Web of Science ®Google Scholar
• Fussey SP, Guest JR, James OF, et al. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988;85:8654-8
   PubMed Web of Science ®Google Scholar
• Yeaman SJ, Fussey SP, Danner DJ, et al. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988;1:1067-70
   PubMed Web of Science ®Google Scholar
• Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev 2014;13:441-4
   PubMed Web of Science ®Google Scholar
• Mattalia A, Quaranta S, Leung PS, et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998;27:656-61
   PubMed Web of Science ®Google Scholar
• Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010;52:745-58
   PubMed Web of Science ®Google Scholar
• Goudie RB, Macsween RN, Goldberg DM. Serological and histological diagnosis of primary biliary cirrhosis. J Clin Pathol 1966;19:527-38
   PubMed Web of Science ®Google Scholar
• Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-85
   PubMed Web of Science ®Google Scholar
• Parikh-Patel A, Gold EB, Worman H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 2001;33:16-21
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chretien Y, Chazouilleres O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010;53:162-9
   PubMed Web of Science ®Google Scholar
• Rieger R, Gershwin ME. The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 2007;28:76-84
   PubMed Web of Science ®Google Scholar
• Long SA, Van de Water J, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis: the role of xenobiotics. Autoimmun Rev 2002;1:37-42
   PubMedGoogle Scholar
• Fussey SP, Ali ST, Guest JR, et al. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci USA 1990;87:3987-91
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Baum H, Grasso A, et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004;40:31-9
   PubMed Web of Science ®Google Scholar
• Rieger R, Leung PS, Jeddeloh MR, et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 2006;27:7-16
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Lian ZX, Leung PS, et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 2008;48:531-40
   PubMed Web of Science ®Google Scholar
• Mendes F, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Gastroenterol Clin North Am 2008;37:479-84; viii
   PubMed Web of Science ®Google Scholar
• Oertelt S, Rieger R, Selmi C, et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007;45:659-65
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27
   PubMed Web of Science ®Google Scholar
• Szostecki C, Krippner H, Penner E, et al. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin Exp Immunol 1987;68:108-16
   PubMed Web of Science ®Google Scholar
• Remmel T, Piirsoo A, Koiveer A, et al. Clinical significance of different antinuclear antibodies patterns in the course of primary biliary cirrhosis. Hepatogastroenterology 1996;43:1135-40
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-7
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528-32
   PubMed Web of Science ®Google Scholar
• Powell F, Schroeter AL, Dickson ER. Antinuclear antibodies in primary biliary cirrhosis. Lancet 1984;1:288-9
   PubMed Web of Science ®Google Scholar
• Zuchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997;26:1123-30
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Cassani F, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002;127:172-5
   PubMed Web of Science ®Google Scholar
• Sternsdorf T, Guldner HH, Szostecki C, et al. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995;42:257-68
   PubMed Web of Science ®Google Scholar
• Janka C, Selmi C, Gershwin ME, et al. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology 2005;41:609-16
   PubMed Web of Science ®Google Scholar
• Granito A, Yang WH, Muratori L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010;105:125-31
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Hohenuer H, Hitchman E, et al. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996;110:840-7
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135-44
   PubMed Web of Science ®Google Scholar
• Courvalin JC, Lassoued K, Worman HJ, et al. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990;172:961-7
   PubMed Web of Science ®Google Scholar
• Worman HJ, Yuan J, Blobel G, et al. A lamin B receptor in the nuclear envelope. Proc Natl Acad Sci USA 1988;85:8531-4
   PubMed Web of Science ®Google Scholar
• Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 1993;178:2237-42
   PubMed Web of Science ®Google Scholar
• Gores GJ, Wiesner RH, Dickson ER, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989;96:1552-9
   PubMed Web of Science ®Google Scholar
• Ali AH, Sinakos E, Silveira MG, et al. Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol 2011;45:e66-71
   PubMed Web of Science ®Google Scholar
• Ikeda F, Okamoto R, Baba N, et al. Prevalence and associated factors with esophageal varices in early primary biliary cirrhosis. J Gastroenterol Hepatol 2012;27:1320-8
   PubMed Web of Science ®Google Scholar
• Colina F, Pinedo F, Solis JA, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 1992;102:1319-24
   PubMed Web of Science ®Google Scholar
• Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 2003;7:901-10
   PubMedGoogle Scholar
• Pares A, Guanabens N, Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005;17:311-15
   PubMed Web of Science ®Google Scholar
• Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316-23
   PubMed Web of Science ®Google Scholar
• Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145-51
   PubMed Web of Science ®Google Scholar
• Guanabens N, Pares A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005;42:573-7
   PubMed Web of Science ®Google Scholar
• Guanabens N, Monegal A, Cerda D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013;58:2070-8
   PubMed Web of Science ®Google Scholar
• Treeprasertsuk S, Silveira MG, Petz JL, et al. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011;18:375-81
   PubMed Web of Science ®Google Scholar
• Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762-71
   PubMed Web of Science ®Google Scholar
• Gregory WL, Game FL, Farrer M, et al. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 1994;105:43-50
   PubMed Web of Science ®Google Scholar
• Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51:265-9
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Emond MJ, Sadowski JA, et al. Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol 1997;92:2059-61
   PubMed Web of Science ®Google Scholar
• Phillips JR, Angulo P, Petterson T, et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001;96:2745-50
   PubMed Web of Science ®Google Scholar
• Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis 2014;34:352-60
   PubMed Web of Science ®Google Scholar
• Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301
   PubMed Web of Science ®Google Scholar
• Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76
   PubMed Web of Science ®Google Scholar
• Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009;104:1420-5
   PubMed Web of Science ®Google Scholar
• Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007;102:1244-50
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Taniai M, Hashimoto E, et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: importance of corticosteroid therapy. Hepatol Res 2014;44:947-55
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Bonder A, Ruthazer R, et al. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010;55:3207-17
   PubMed Web of Science ®Google Scholar
• Giljaca V, Poropat G, Stimac D, et al. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010(5):CD004385
   PubMed Web of Science ®Google Scholar
• Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005;42:1184-93
   PubMed Web of Science ®Google Scholar
• Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013;108:933-41
   PubMed Web of Science ®Google Scholar
• Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012;55:512-21
   PubMed Web of Science ®Google Scholar
• Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-7
   PubMed Web of Science ®Google Scholar
• Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56
   PubMed Web of Science ®Google Scholar
• Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-18
   PubMed Web of Science ®Google Scholar
• Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-54
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16
   PubMed Web of Science ®Google Scholar
• Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-7
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715-20
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137-40
   PubMed Web of Science ®Google Scholar
• Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-5
   PubMed Web of Science ®Google Scholar
• Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007;5:1313-15
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007;13:1236-45
   PubMed Web of Science ®Google Scholar
• Milkiewicz P, Gunson B, Saksena S, et al. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors. Transplantation 2000;70:477-80
   PubMed Web of Science ®Google Scholar
• Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20:211-20
   PubMed Web of Science ®Google Scholar
• Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis 2008;12:461-72; xi
   PubMed Web of Science ®Google Scholar
• Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001;33:22-7
   PubMed Web of Science ®Google Scholar
• Neuberger J, Gunson B, Hubscher S, et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10:488-91
   PubMed Web of Science ®Google Scholar
• Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998;28:33-8
   PubMed Web of Science ®Google Scholar
• Markus BH, Dickson ER, Grambsch PM, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989;320:1709-13
   PubMed Web of Science ®Google Scholar
• Dubel L, Farges O, Bismuth H, et al. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J Hepatol 1995;23:674-80
   PubMed Web of Science ®Google Scholar
• Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7
   PubMed Web of Science ®Google Scholar
• Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of Alkaline Phosphatase and Bilirubin are Surrogate Endpoints of Outcomes of Patients with Primary Biliary Cirrhosis - an International Follow-up Study. Gastroenterology 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012;17:988-97
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-72
   PubMed Web of Science ®Google Scholar
• Mason A, Luketic V, Lindor K, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to Ursodeoxycholic acid. J Hepatol 2010;52:S1-S21
   PubMed Web of Science ®Google Scholar